tiprankstipranks
Trending News
More News >
PolyPeptide Group AG (CH:PPGN)
:PPGN

PolyPeptide Group AG (PPGN) AI Stock Analysis

Compare
0 Followers

Top Page

CH

PolyPeptide Group AG

(PPGN)

Rating:61Neutral
Price Target:
CHF21.50
▲(0.00%Upside)
PolyPeptide Group AG's overall score is driven by strong cash flow management and positive short-term technical indicators, offset by profitability issues and unappealing valuation metrics. Addressing profitability would significantly enhance the company's financial standing.

PolyPeptide Group AG (PPGN) vs. iShares MSCI Switzerland ETF (EWL)

PolyPeptide Group AG Business Overview & Revenue Model

Company DescriptionPolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
How the Company Makes MoneyPolyPeptide Group AG generates revenue primarily through its contract manufacturing services for peptide-based APIs. The company operates a business-to-business model, offering custom synthesis, development, and large-scale manufacturing solutions to pharmaceutical and biotech companies. Revenue streams are largely driven by long-term partnerships and contracts with these clients, who rely on PolyPeptide for its specialized capabilities in peptide production. In addition to manufacturing contracts, the company benefits from its established reputation and expertise, which contribute to a steady flow of orders and collaborations. The company's earnings are further supported by its focus on innovation and quality, ensuring compliance with regulatory standards and meeting the evolving needs of the pharmaceutical industry.

PolyPeptide Group AG Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
320.37M338.69M320.37M280.98M282.13M224.30M
Gross Profit
4.77M39.27M4.64M51.99M99.70M73.19M
EBIT
-33.83M-7.36M-36.47M12.53M67.40M44.31M
EBITDA
-12.31M28.42M-22.15M35.72M83.35M58.55M
Net Income Common Stockholders
-51.44M-19.56M-51.44M7.77M47.26M31.34M
Balance SheetCash, Cash Equivalents and Short-Term Investments
4.38M68.28M95.71M37.53M136.30M17.21M
Total Assets
76.29M756.58M689.09M575.78M595.04M375.98M
Total Debt
8.84M94.12M113.66M21.22M18.00M37.43M
Net Debt
4.46M25.84M17.96M-16.31M-118.30M20.23M
Total Liabilities
38.93M399.33M307.86M154.10M173.87M198.31M
Stockholders Equity
37.35M357.24M381.23M421.68M421.17M177.66M
Cash FlowFree Cash Flow
-16.41M2.43M-20.25M-69.64M-16.61M8.86M
Operating Cash Flow
36.48M89.40M36.48M5.46M57.35M49.48M
Investing Cash Flow
-59.51M-91.02M-59.51M-78.44M-80.84M-42.56M
Financing Cash Flow
84.55M-25.32M84.55M-26.87M130.93M-6.73M

PolyPeptide Group AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price21.50
Price Trends
50DMA
18.38
Positive
100DMA
20.04
Positive
200DMA
24.79
Negative
Market Momentum
MACD
0.75
Negative
RSI
60.29
Neutral
STOCH
73.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:PPGN, the sentiment is Positive. The current price of 21.5 is above the 20-day moving average (MA) of 20.17, above the 50-day MA of 18.38, and below the 200-day MA of 24.79, indicating a neutral trend. The MACD of 0.75 indicates Negative momentum. The RSI at 60.29 is Neutral, neither overbought nor oversold. The STOCH value of 73.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:PPGN.

PolyPeptide Group AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
CHF729.99M
3.15%62.88%
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
CHF1.01B7.6929.55%3.22%
CHF4.16B34.618.87%1.53%
$5.41B26.0618.36%0.42%
CHF26.82B131.82
0.13%
CHMED
CHF1.06B288.01
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:PPGN
PolyPeptide Group AG
21.25
-11.20
-34.51%
GB:0RGI
COSMO Pharmaceuticals N.V.
60.30
-8.67
-12.57%
GB:0QND
Bachem Holding AG
55.30
-22.86
-29.25%
SGFEF
Siegfried Holding AG
109.92
13.83
14.39%
CH:GALD
Galderma Group AG
112.00
37.04
49.41%
CH:MED
Medartis Holding AG
77.10
4.60
6.34%

PolyPeptide Group AG Corporate Events

PolyPeptide Expands Credit Facility to Fuel Growth
May 23, 2025

PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.

The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

PolyPeptide Group AG’s Shareholders Approve Key Proposals at 2025 General Meeting
Apr 9, 2025

At the fourth ordinary General Meeting, PolyPeptide Group AG’s shareholders approved all Board of Directors’ proposals, including re-elections and the introduction of new authorized and conditional share capital. These decisions are expected to strengthen the company’s financial structure and governance, potentially enhancing its market position and stakeholder confidence.

PolyPeptide Group AG Announces Agenda for 2025 General Meeting
Mar 18, 2025

PolyPeptide Group AG has announced the agenda for its fourth ordinary General Meeting in April 2025, where key board members will stand for re-election, and a new independent member, Jo LeCouilliard, is proposed for election. The meeting will also address the introduction of authorized and conditional share capital to enhance financial and strategic flexibility, alongside other standard agenda items such as re-election of auditors and approval of financial statements.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.